Received Jan 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RV1 | ROTAVIRUS (ROTARIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | UNK | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 2 | UNK | — |
The patient had received 2 doses of the 3 dose series of Rotateq. Instead of getting the 3rd dose of Rotateq, the office made a mistake and gave the last dose with Rotarix; This non-serious case was reported by a nurse via sales rep and described the occurrence of interchange of vaccine products in a infant patient who received Rota (Rotarix liquid formulation) for prophylaxis. Co-suspect products included ROTAVIRUS VACCINE LIVE REASSORT ORAL 5V (ROTATEQ) for prophylaxis. Previously administered products included Rotateq (Received 1st dose of Rotateq vaccine on an unknown date). On an unknown date, the patient received the 3rd dose of Rotarix liquid formulation and the 2nd dose of ROTATEQ. On an unknown date, an unknown time after receiving Rotarix liquid formulation and an unknown time after receiving ROTATEQ, the patient experienced interchange of vaccine products (Verbatim: The patient had received 2 doses of the 3 dose series of Rotateq. Instead of getting the 3rd dose of Rotateq, the office made a mistake and gave the last dose with Rotarix). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 09-JAN-2026 The patient had received 2 doses of the 3 dose series of Rotateq. Instead of getting the 3rd dose of Rotateq, the office made a mistake and gave the last dose with Rotarix. The batch number was not provided, and we are unable to contact the reporter.